| Document |
Document Title |
|
WO/2007/101347A1 |
Disclosed herein are compounds as resented by Formula (I): wherein R1,R2, R3, R4, n, W, A, and Q are as defined herein. The compounds of formula (I) are useful as antagonists of the IAPs via binding to BIR domain. The compounds are usefu...
|
|
WO/2007/093507A1 |
The invention is concerned with novel heterobicyclic derivatives of formula (I) wherein R1, R2, R3, R4, R5, R6, V, W, X and Y are as defined in the description and in the claims, as well as physiologically acceptable salts and esters the...
|
|
WO/2007/064316A1 |
The invention encompasses a series cyclic bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. ...
|
|
WO2007037518A9 |
The invention is intended to provide a novel compound which is useful as an antibacterial agent and a manufacturing intermediate thereof and relates to a mutilin derivative represented by the formula (I) which is useful as an antibacteri...
|
|
WO/2007/053618A1 |
Compounds are described that are prodrugs to active compounds that modulate a muscarinic receptor. In some cases, the compounds are prodrugs to. N-desmethylclozapine. The compounds may be used to treat neuropsychiatric disorders.
|
|
WO/2007/050425A2 |
A compound of formula I,wherein A, X, q, R1, R2a, R2b, R2c, R3a, and R3b are defined herein, useful as liver X receptor modulator.
|
|
WO/2007/047737A1 |
Disclosed herein is a compound of Formula (I). Also disclosed herein is a method of modulating the activity of a cannabinoid receptor using a compound of Formula (I). Furthermore, disclosed herein is a method of treating a disease or con...
|
|
WO/2007/024501A2 |
Nitric Oxide (NO)-releasing polymers useful as implantable medical devices and coatings therefore are provided. Specifically the implantable medical devices and/or coatings comprise NO-releasing biodegradable polymers derived from [1,4] ...
|
|
WO/2007/004959A1 |
The present invention relates to new compounds of formula (I), or salts, solvates or solvated salts thereof, process for their preparation and to new intermediates used in the preparation thereof, pharmaceutical compositions containing s...
|
|
WO2006117669B1 |
The present invention is directed to compounds of formula (I), and pharmaceutically acceptable salts and solvates thereof, their synthesis, and their use as HSP-90 inhibitors.
|
|
WO/2007/004960A1 |
The present invention relates to new compounds of formula I, or salts, solvates or solvated salts thereof, process for their preparation and to new intermediates used in the preparation thereof, pharmaceutical compositions containing sai...
|
|
WO/2006/132295A1 |
Disclosed is a compound represented by the general formula (1) or a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug which has a prophylactic or therapeutic effect on various diseases such as hypertension,...
|
|
WO/2006/101496A1 |
The present invention provides novel 1,4-benzothiazepine intermediates and derivatives, methods for synthesizing same, and methods for assaying same. The present invention also provides methods for using these novel compounds to limit or...
|
|
WO/2006/097449A1 |
New N-hydroxyamides of n-alkyl carboxylic acids omega substituted with suitable tricyclic systems characterised by a central 7-membered ring, having activity as inhibitors of histone deacetylase (HDAC).
|
|
WO/2006/095187A1 |
A compound selected from (1 S)-8-cyano-5-methyl-1-(3-methoxy)phenyl-1,3,4,6-tetrahydro-5
H-benz[f]-2,5- oxazocine; (1 R)-8-cyano-5-methyl-1-(3-methoxy)phenyl-1,3,4,6-tetrahydro-5
H-benz[f]-2,5- oxazocine; (1 S)-8-cyclopropyl-5-methyl-1-(...
|
|
WO/2006/078724A2 |
Disclosed are compounds of the Formula (I) and diastereomers, tautomers, solvates, metabolites, and pharmaceutically acceptable salts thereof, wherein X, A, L and Y are as defined herein. Such compounds are useful in the treatment of imm...
|
|
WO/2006/065218A1 |
The present invention relates to novel molecular probes having the formula (I) (I) useful for the characterization, detection, localization and isolation of the &gammad -secretase enzyme.
|
|
WO/2006/061136A2 |
The invention relates to compounds of the general Formula (I) wherein R is halogen, lower alkyl or lower alkyl substituted by halogen; R1 is hydrogen, lower alkyl or lower alkyl substituted by halogen or hydroxy, or is lower alkenyl, -(C...
|
|
WO/2006/046123A2 |
The present invention relates to new compounds represented by Formula I: wherein M represents a macrolide subunit of the substructure VIII: L represents the chain of the substructure IX or XIII: Z represents the steroid or nonsteroidal s...
|
|
WO/2006/047740A2 |
Novel compounds useful for inhibiting the 90kDa heat shock proteins containing a quinone-like moiety and a di-hydroxy phenol like moiety, similar to geldanamycin and radicicol.
|
|
WO/2006/037775A1 |
Enantiopure heterocyclic compound Enantiopure heterocyclic compound of formula (I) in which J is chosen from C, N, O and S; Z is H or a group for protecting the amino functional group, R3 denotes H or an organic residue, m is 0, 1 or 2 a...
|
|
WO/2006/023242A1 |
The present invention is directed to novel benzoxazepine derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and diseases mediated by an estrogen receptor.
|
|
WO/2006/021213A2 |
The present invention concerns compounds inter alia according to general formula: (1a). Compounds according to the invention are vasopressin V1a receptor antagonists. Pharmaceutical compositions of the compounds are useful as treatment o...
|
|
WO/2006/020817A1 |
The present invention discloses novel 5-HT receptor binding agents of Formula 3, wherein X is -CH or -N-. Y is selected from the group consisting of -CR10R11, -NR12, -0-, -S-, -SO-, and -SO2-. R1 to R12 are various substituents selected ...
|
|
WO/2006/004841A2 |
Galmic, a non-peptide galanin receptor agonist, affects behaviors in seizure, pain and forced swim tests.
|
|
WO/2005/121133A1 |
The present invention provides an industrial production method with a short process having a high yield of an aliphatic cyclic carboxamide having carboxyl group, which comprises reacting functional group-selectively using an inexpensive ...
|
|
WO/2005/103019A1 |
Compounds having therapeutic utility are of general formula (1) wherein R, is H, C 1-C6 alkyl optionally substituted with F or C3-C6 cycloalkyl or C2-C4 alkenyl; A is O, CH2 or S(O)n where n is 0-2; one of W, X, Y and Z is N, CH or CR3 a...
|
|
WO/2005/095366A1 |
This invention provides progesterone receptor modulators having the structure: wherein R1 to R7, X, and Q are as defined in the specification; or a pharmaceutically acceptable salt thereof.
|
|
WO/2005/088307A1 |
Immunoassays for the detection of everolimus are provided. Compounds for producing antibodies for everolimus, as well as antibodies produced therefrom, are also provided.
|
|
WO/2005/086951A2 |
Prodrugs of cyclic anthracyclin toxins comprising a hypoxia-activated trigger and are disclosed. In addition, methods of treating cancer using the compounds of the invention are disclosed.
|
|
WO/2005/077463A2 |
One aspect of the present invention relates to a method of treating of drug addiction or drug dependence in a mammal, comprising the step of administering to a mammal in need thereof a therapeutically effective amount of a heterocyclic c...
|
|
WO/2005/072741A1 |
The invention relates to dibenzoxazepines and to a method for the production thereof, use thereof in the treatment and/or prophylaxis of illnesses, in addition to the use thereof in the production of medicaments for treating and/or for t...
|
|
WO2005040142B1 |
Novel difluorinated amide derivatives of Formula (II) as inhibitors of cathepsin S, K, B, and L, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making.
|
|
WO/2005/056539A2 |
A process for increasing the optical purity of a mixture of enantiomers of nefopam uses a substantially single enantiomer of a O,O-diaroyltartaric acid as a resolving agent, via a bisnefopam salt of the acid. This salt is new.
|
|
WO/2005/052542A2 |
New derivatives of FK 506 are disclosed. These new derivatives and other derivatives that are useful for determining the levels of FK 506 in a sample are also provided as are assay procedures and kits for use in determining the levels of...
|
|
WO/2005/018545A2 |
The present invention is directed to compounds which are inhibitors of the beta-secretase enzyme and that are useful in the treatment or prevention of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. ...
|
|
WO/2004/100958A1 |
The invention relates to benzoxazepinone derivatives of formula (I) wherein R1 is hydrogen, lower alkoxy, halogen or -NR'R'; n is 1 or 2; R',R' are independently from each other hydrogen or lower alkyl; R2 is hydrogen, lower alkyl, -(CH2...
|
|
WO/2004/093796A2 |
Lactam derivatives of the general formula (I), are disclosed. Pharmaceutical compositions containing the compounds and methods for their use are also disclosed.
|
|
WO/2004/091628A1 |
An agent for controlling the function of an RFRP receptor, characterized by containing either a compound represented by the formula (I) [wherein ring A represents an optionally substituted aromatic ring; ring B represents an optionally s...
|
|
WO/2004/080391A2 |
This invention relates to novel macrolides, to the preparation of novel macrolides, to the use of such novel macrolides for preventing, treating, or ameliorating various conditions, and to the use of such novel macrolides as antibacteria...
|
|
WO/2004/067008A1 |
It is intended to provide a TGR5 receptor agonist containing a fused ring compound represented by the following general formula, its salt or a prodrug thereof: (I) wherein the ring A represents an optionally substituted aromatic ring; an...
|
|
WO/2004/064865A1 |
It is intended to provide a novel drug useful as a skeletal muscle protecting agent which contains a compound having an effect of inhibiting squalene synthase, its salt or a prodrug thereof.
|
|
WO/2004/056182A1 |
Use of compounds of formula (I): wherein X is S, O, S=O, SO2, NRa, or CRbRc;R1,R2 are halogen, OH, SH, NH2, CN, NO2, alkyl, alkoxy, alkylamino, dialkylamino, alkylthio, alkenyl, alkenyloxy, alkenylamino, alkenylthio, alkynyl, alkynyloxy,...
|
|
WO/2004/056788A1 |
Compounds of the general formula (1), wherein one of W, X, Y and Z is N or CR4 and the others are each CH; and R4 is a specified substituent. These compounds inhibit monoamine reuptake, and are useful in the treatment of pain, emesis dep...
|
|
WO/2004/041209A2 |
Substituted benzoimidazole compounds useful as anti-infectives that decrease resistance, virulence, or growth of microbes are provided. Methods of making and using substituted benzoimidazole compounds, as well as pharmaceutical preparati...
|
|
WO/2004/033437A1 |
The invention relates to compounds, a method for the production thereof, pharmaceutical compositions containing said compounds and to the utilization thereof in the treatment and/or prophylaxis of diseases in human beings or animals, esp...
|
|
WO/2004/031154A1 |
Compounds having the formula (I) pharmaceutical compositions containing them and their methods of use for the treatment of neurological disorders related to amyloid ß protein production and neurological disorders such as Alzheimer's dis...
|
|
WO/2004/026292A1 |
Antitussives containing as the active ingredient compounds represented by the general formula (I) or salts thereof: (I) (wherein A is alkoxycarbonylalkyl or the like and R is optionally protected hydroxyl, or A and R may be united to for...
|
|
WO/2004/016576A1 |
A compound represented by the general formula (I) [wherein ring A represents an optionally substituted 5- to 8-membered ring; ring B represents a further optionally substituted 4- to 10-membered ring; ring C represents a further optional...
|
|
WO/2004/014851A2 |
The present invention relates to compounds that are capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases. The compounds of the instant invention possess a co...
|
